No­vavax fo­cus­es on vari­ant-spe­cif­ic vac­cines in ex­pand­ed deal with South Ko­re­an man­u­fac­tur­er

The roller­coast­er ride for No­vavax’s Covid-19 vac­cine has fi­nal­ly re­sult­ed in an emer­gency use au­tho­riza­tion from the FDA. How­ev­er, as the Omi­cron vari­ant spreads, the com­pa­ny is turn­ing to a Ko­re­an man­u­fac­tur­er to up­grade its ca­pa­bil­i­ties.

The Mary­land-based com­pa­ny inked agree­ments with SK bio­science for the man­u­fac­tur­ing and sup­ply of a ver­sion of its vac­cine that’s specif­i­cal­ly de­signed to pro­tect against Omi­cron, No­vavax an­nounced on Tues­day. SK al­so com­mit­ted to man­u­fac­tur­ing No­vavax’s vac­cine in pre­filled sy­ringes, though the fi­nan­cial de­tails were not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER